Perspective Therapeutics (CATX) FCF Margin (2010 - 2023)
Perspective Therapeutics (CATX) posted FCF Margin of 185.58% for Q4 2023, up 139.23% sequentially from 473.09% in Q3 2023.
Perspective Therapeutics (CATX) FCF Margin (2010 - 2023) Analysis & Trends
Perspective Therapeutics has reported FCF Margin for 14 years, with the latest figure at 185.58% in Q4 2023.
- Quarterly FCF Margin changed N/A year-over-year to 185.58% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 4489.95% (changed N/A YoY) and the FY2023 annual result came in at 2648.88%, changed N/A from the prior year.
- FCF Margin rose to 185.58% in Q4 2023 per CATX's latest filing, from 473.09% in the prior quarter.
- Over five years, FCF Margin peaked at 185.58% in Q4 2023 and troughed at 575.13% in Q2 2023.
- A 5-year average of 107.07% and a median of 52.88% in 2019 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2021 and 2023: FCF Margin soared 13302 bps in 2021, then slumped 49303 bps in 2023.
- Over 5 years, FCF Margin stood at 62.74% in 2019, then soared by 45 bps to 34.76% in 2020, then surged by 383 bps to 98.26% in 2021, then plunged by 190 bps to 88.32% in 2022, then soared by 310 bps to 185.58% in 2023.
- According to Business Quant data, FCF Margin over the past three periods registered 185.58%, 473.09%, and 575.13% for Q4 2023, Q3 2023, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.12 Bn | 193.52 Bn | 7.27 Bn | 15.81% |
| 2 | Stryker | 128.79 Bn | 125.32 Bn | 4.50 Bn | 16.07% |
| 3 | Medtronic | 119.30 Bn | 110.08 Bn | 6.41 Bn | 21.26% |
| 4 | Boston Scientific | 73.50 Bn | 72.96 Bn | 3.85 Bn | 23.50% |
| 5 | Edwards Lifesciences | 52.11 Bn | 47.86 Bn | 1.35 Bn | 33.60% |
| 6 | Dexcom | 34.62 Bn | 32.67 Bn | 830.00 Mn | 14.10% |
| 7 | GE HealthCare Technologies | 34.05 Bn | 31.94 Bn | 2.18 Bn | 1.28% |
| 8 | Koninklijke Philips | 26.42 Bn | 23.10 Bn | 4.55 Bn | 5.32% |
| 9 | Steris | 23.15 Bn | 22.67 Bn | 684.20 Mn | 18.73% |
| 10 | Perspective Therapeutics | 387.89 Mn | 387.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 185.58% |
| Sep 30, 2023 | -473.09% |
| Jun 30, 2023 | -575.13% |
| Mar 31, 2023 | -481.05% |
| Sep 30, 2022 | -88.32% |
| Jun 30, 2022 | -82.11% |
| Mar 31, 2022 | -49.83% |
| Dec 31, 2021 | 98.26% |
| Sep 30, 2021 | -83.39% |
| Mar 31, 2021 | -27.46% |
| Dec 31, 2020 | -34.76% |
| Sep 30, 2020 | -18.92% |
| Jun 30, 2020 | -38.31% |
| Mar 31, 2020 | -31.46% |
| Dec 31, 2019 | -62.74% |
| Sep 30, 2019 | -32.44% |
| Jun 30, 2019 | -55.93% |
| Mar 31, 2019 | -76.20% |
| Dec 31, 2018 | -64.34% |
| Sep 30, 2018 | -110.50% |